Financial Times Global Pharma and Biotech Summit
5-7 November 2024, digital and in-person event
Driving progress in life sciences, from innovation to access
The world of life sciences is in a period of relentless disruption. Advances in technology are transforming research and development. Innovative treatments such as mRNA vaccines and cell therapies are reshaping healthcare as we know it. Meanwhile, companies face the challenge of bringing products to market in an unsettled regulatory environment.
The FT Global Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on what’s new in areas such as drug discovery, clinical trials, market access and patient engagement.
ICON speakers:
Tony Clarke
7 November 2024 - 9:50 - 10:30 AM
Panel: “From hype to reality – How AI is actually being used inside biopharma In-Person & Online”
The power of AI to design novel molecules and cut drug development times holds great promise for life sciences innovation. Applications are advancing all the time, but the path to successful adoption at scale is still unclear.
- How can AI algorithms be trained on diverse datasets to improve drug discovery, and what limitations exist within current applications?
- What differences of opinion exist on how best to leverage AI and integrate it into pharma operating models?
- How could any forthcoming regulation of AI impact its application in life sciences?
Other featured speakers include:
- Virginia Acha – Associate Vice President and Global Lead, Global Evidence and Regulatory Policy, MSD
- Rohit Alimchandani – Head of Life Sciences, UK and Ireland, Cognizant
- Annaliesa Anderson – Senior Vice President, Head of Vaccine Research and Development, Pfizer
- Seyda Atadan Memis – General Manager, UK and Ireland, Takeda
- Kylie Bromley – Vice President and Managing Director, United Kingdom and Ireland, Biogen
- Fiona Bride – Director of Medicines Value and Access, NHS England
- Robert A. Bradway – Chairman and CEO, Amgen
- Francesca Ceddia – Chief Medical Affairs Officer, Moderna
- Michael Elliott – Vice President, Medical Affairs, Europe, Canada and Australasia, Gilead Sciences
- Sebastian Guth – President, Bayer US, Chief Operating Officer, Bayer Pharmaceuticals
- Demis Hassabis – CEO, Google DeepMind and Isomorphic Labs
- Waheed Jamal – Corporate Vice President, Head of Medicine, Cardiovascular, Renal and Metabolism, Boehringer Ingelheim
- Ken Keller – Chairman of the Board, President and CEO, Daiichi Sankyo, Inc.
- Anja König – Global Head, Novartis Venture Fund
- Kasim Kutay – CEO, Novo Holdings
- Mishal Patel – Corporate Vice President, AI and Digital Research, Novo Nordisk
- Kirsten Shastri – Head of Life Sciences, Tokio Marine Kiln
- Monica Shaw – Senior Vice President, Head of European Markets, Bristol Myers Squibb
- Kris Sterkens – Company Group Chairman, EMEA, Johnson & Johnson Innovative Medicine
- Padraic Ward – Head Pharma International, Roche
- Christophe Weber – President and CEO, Takeda
- Emma Walmsley – CEO, GSK
- Doina Ionescu - Managing Director, UK and Ireland, Merck Healthcare